Dr Bente Talseth-palmer
Biomedical Sciences and Pharmacy
New Castle University
Australia
Biography
Dr Talseth-Palmer was awarded her PhD in January 2008, which was undertaken in the HMRI's NBN Telethon Childhood Cancer research laboratory. She was awarded the research higher degree award for excellence in the Faculty of Health in recognition of outstanding research achievement for her Doctor of Philosophy research thesis. In January 2008, she successfully obtained a Gladys M. Brawn Memorial Post-Doctoral fellowship from the University of Newcastle and is now a part of the HMRI's, Information-Based Medicine Research Program. Prior to completing her PhD, Dr Talseth-Palmer completed a Bachelor of Medical Laboratory Technology in Norway in 1999 and a Masters of Genetic Counselling at the University of Newcastle in 2004. Between 1999 and 2003, Dr Talseth-Palmer worked as a research assistant focusing on genetic research both in Iceland and Norway. In 2006, Dr Talseth-Palmer was awarded a travel grant to attend the 11th International Congress of Human Genetics by the Human Genetics Society of Australasia (HGSA). In 2008, she was nominated as 10 of the best research showcases at the University of Newcastle and, in 2009, she was awarded the Hunter Medical Research Institute (HMRI) Pulse Education Prize, an award presented to outstanding early career researchers. Dr Talseth-Palmer is also an invited reviewer for the journal, Cancer Causes & Control.
Research Interest
Genetics, Public Health and Health Services, Oncology and Carcinogenesis
Publications
-
Li J, Liu H, Liu J, Fu XA, Yu Y, Yu G, Chen S, Chu T, Lu N, Bao F, Yuan C. Association study of the single nucleotide polymorphisms of PARK2 and PACRG with leprosy susceptibility in Chinese population. European journal of human genetics: EJHG. 2012 May 1;20(5):488.
-
Talseth-Palmer BA, Bowden NA, Meldrum C, Nicholl J, Thompson E, Friend K, Liebelt J, Bratkovic D, Haan E, Yu S, Scott RJ. A 1q44 deletion, paternal UPD of chromosome 2 and a deletion due to a complex translocation detected in children with abnormal phenotypes using new SNP array technology. Cytogenetic and genome research. 2009;124(1):94-101.
-
Talsethâ€Palmer BA, Wijnen JT, Brenne IS, Jagmohanâ€Changur S, Barker D, Ashton KA, Tops CM, Evans TJ, McPhillips M, Groombridge C, Suchy J. Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23. 3 and 11q23. 1 in MLH1 mutation carriers. International journal of cancer. 2013 Apr 1;132(7):1556-64.
